Regulation of neuregulin-mediated acetylcholine receptor synthesis by protein tyrosine phosphatase SHP2 by Tanowitz, Michael et al.
Regulation of Neuregulin-Mediated Acetylcholine Receptor
Synthesis by Protein Tyrosine Phosphatase SHP2
Michael Tanowitz,1 Jutong Si,1 De-Hua Yu,2 Gen-Sheng Feng,2 and Lin Mei1
1Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 22908, and 2Department
of Biochemistry and Molecular Biology and Walther Oncology Center, Indiana University, Indianapolis,
Indiana 46202-5424
Synapse-specific expression of the nicotinic acetylcholine re-
ceptor (AChR) is believed to be mediated by neuregulin, an
epidermal growth factor-like trophic factor released by somatic
motoneurons at the neuromuscular junction (NMJ). Neuregulin
stimulates ErbB2, ErbB3, and ErbB4, members of the ErbB
family of receptor tyrosine kinases. SHP2 is a cytoplasmic
protein tyrosine phosphatase containing two Src homology 2
domains near its N terminus, and has been shown to be a
positive mediator of mitogenic responses to various growth
factors. We found that SHP2 interacted with ErbB2 and ErbB3
after neuregulin stimulation of muscle cells. Expression of
SHP2 in C2C12 mouse muscle cells attenuated the neuregulin-
induced expression of an AChR e-promoter reporter gene,
whereas a catalytically inactive SHP2 mutant or a mutant lack-
ing the N-terminal Src homology 2 (SH2) domain enhanced
reporter expression, suggesting that SHP2 negatively regulates
the neuregulin signaling pathway. In fibroblast cells that express
a mutant SHP2 with a targeted deletion of the N-terminal SH2
domain, neuregulin-mediated activation of the Ras/Raf/extra-
cellular signal-regulated kinase cascade was enhanced. Fur-
thermore, we found that SHP2 immunoreactivity colocalized
with the staining of a-bungarotoxin, a marker of the NMJ. These
results demonstrate a negative role of SHP2 in the neuregulin
signal that leads to AChR gene expression at the NMJ.
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The transcription of genes encoding AChR subunits (a, b, g, or e,
and d) is highest in nuclei localized to the synaptic regions of
muscle, thereby contributing to the high density of AChRs at the
postjunctional membrane. Such synapse-specific transcription is
believed to be mediated by neuregulin, a trophic factor used by
motoneurons to stimulate AChR synthesis (Jessell et al., 1979;
Falls et al., 1993; Loeb and Fischbach, 1995). Neuregulin (also
known as neu differentiation factor, glial growth factor, and
acetylcholine receptor inducing activity) (Lemmon and Scles-
singer, 1994) activates ErbB2, ErbB3, and ErbB4, members of the
ErbB family of protein tyrosine kinases (Chu et al., 1995; Jo et al.,
1995; Zhu et al., 1995; Si et al., 1996). Both neuregulin and ErbB
proteins are localized to the adult neuromuscular junction (NMJ)
(Altiok et al., 1995; Moscoso et al., 1995; Zhu et al., 1995), thus
fulfilling a spatial requirement for synapse-specific signal trans-
duction. Mice that are heterozygous for one neuregulin allele
show deficiencies in neuromuscular transmission and have 50%
fewer AChRs at the NMJ (Sandrock et al., 1997), although
homozygous mice die before NMJ formation because of devel-
opmental defects of the heart (Meyer and Birchmeier, 1995).
Current evidence therefore supports neuregulin as the best can-
didate for the primary signal of synapse-specific transcription.
The neuregulin signaling pathway that leads to AChR gene
expression has become increasingly clear. Neuregulin stimulates
ErbB tyrosine kinases and subsequently the Ras/Raf/MAP ki-
nase signaling cascade (Marte et al., 1995; Si et al., 1996). Both
Ras and Mek are required for neuregulin-stimulated induction of
AChR genes (Si et al., 1996; Tansey et al., 1996; Altiok et al.,
1997). Several studies have implicated Ets proteins, known targets
of the MAP kinase pathway (Marais et al., 1993; Brunner et al.,
1994; O’Hagan and Hassell, 1999), as components of the activated
transcriptional machinery. In the d-subunit promoter, a potential
Ets-protein-binding site was identified as a neuregulin-response
element (NRE) (Fromm and Burden, 1998), and GABPa, an Ets
protein, and GABPb, a dimerization partner, were implicated as
NRE-binding proteins. Unlike the other AChR subunits, expres-
sion of the e subunit is restricted to the synapse at all stages of
development and is therefore the subject of particular attention.
Ets-binding sites in the AChR e 59flanking region also appear to
be necessary for synapse-specific expression (Duclert et al., 1996)
and neuregulin responsiveness (Sapru et al., 1998). We have
reported the requirement of a different non-Ets site for neuregu-
lin induction of the mouse AChR e gene in cultured muscle cells
(Si et al., 1997).
In contrast to the extensive study of downstream mechanisms
contributing to synapse-specific expression, less attention has
focused on upstream mechanisms that may regulate neuregulin
signaling, perhaps because of a presumed similarity to the epi-
dermal growth factor (EGF) pathway. One signaling molecule
known to modulate a large number of receptor-tyrosine kinase
signaling pathways is SHP2. SHP2 (PTP1D, SHPTP2, or Syp) is
a widely expressed cytoplasmic protein tyrosine phosphatase
containing two Src homology 2 domains near its N terminus
(Feng and Pawson, 1994). SHP2 associates with numerous recep-
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tor tyrosine kinases in a stimulation-dependent manner and acts
as a positive regulator of mitogenic responses to EGF, insulin,
and insulin growth factor (IGF)-1 (Feng et al., 1993; Xiao et al.,
1994; Bennett et al., 1996). Although the precise mechanism by
which SHP2 transduces positive signals is unknown, numerous
studies have implicated the requirement of the catalytic activity
of the protein and functional Src homology 2 (SH2) domains.
Expression of an enzymatically inactive SHP2 mutant inhibits
extracellular signal-regulated kinase (ERK) activation in re-
sponse to insulin, IGF-1, and fibroblast growth factor (Noguchi et
al., 1994; Tang et al., 1995; Yamauchi et al., 1995). Cells express-
ing a mutant SHP2 lacking a functional N-terminal SH2 domain
show attenuated ERK activation after EGF, platelet-derived
growth factor (PDGF), and IGF-1 stimulation (Shi et al., 1998).
The role of SHP2 in the regulation of neuregulin signaling,
however, is still unclear. We report here that SHP2 association
with ErbB2 and ErbB3 and tyrosine phosphorylation are in-
creased in neuregulin-stimulated cells. In addition, SHP2 was
found to be localized to the NMJ in vivo. Our results from C2C12
mouse muscle cells and mutant fibroblasts suggest that SHP2
negatively regulates neuregulin signaling.
MATERIALS AND METHODS
Materials. Recombinant neuregulin (rHRG-b1177–244, a peptide of
HRGb1 residues 177–244) was generously provided by Mark Sliwkowski
(Genentech, San Francisco, CA; Holmes et al., 1992). This peptide
stimulates AChR gene expression in myotubes in primary culture (Altiok
et al., 1995; Chu et al., 1995; Si et al., 1996, 1997). Cell culture medium
and components were purchased from Life Technologies (Gaithersburg,
MD). Polyclonal antibodies to ErbB2 (C-18), ErbB3 (C-17) EGF recep-
tor (EGFR) (SC-O3), and monoclonal anti-SHP2 antibody (B-1) were
from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-
phosphotyrosine antibody (RC20) was from Transduction Laboratories
(Lexington, KY). The E10 monoclonal anti-phospho MAP Kinase an-
tibody was purchased from New England BioLabs (Beverly, MA). The
generation of rabbit anti-ERK has been described previously (Shi et al.,
1998). Rat monoclonal Y13–259 anti-Ras antibody was obtained from
culture medium of a hybridoma cell line (CRL-1742; American Type
Culture Collection, Manassas, VA). Anti-Raf antibody, recombinant
glutathione S-transferase-MAP/ERK kinase (GST-MEK), and recombi-
nant GST ERK1 were kindly provided by Dr. Z. Luo (Boston Universi-
ty). All other chemicals were from Sigma (St. Louis, MO).
Cell lines and culture conditions. The wild-type (Shp-21/1) and mutant
(Shp-22/2) embryonic fibroblast cell lines have been described previ-
ously (Shi et al., 1998). C2C12 cells were obtained from Dr. E. S. Ralston
(National Institute of Neurological Disorders and Stroke, National Insti-
tutes of Health, Bethesda, MD), which were a subclone of the C2 cells
originally derived from mouse thigh muscle (Yaffe and Saxel, 1977). The
C2C12 cells were maintained as undifferentiated myoblasts in DMEM
with high glucose supplemented with 20% fetal bovine serum, 0.5%
chicken embryo extract, 2 mM L-glutamine, 100 U/ml penicillin, and 100
mg/ml streptomycin at 37° C in an atmosphere of 5% CO2 and 95%
humidity (Si et al., 1996). Cells were split at ;70% confluence using
0.05% trypsin and 0.02% EDTA in saline. Fusion of myoblasts into
myotubes was induced by culturing myoblasts for 48 hr in differentiation
medium (DM), DMEM supplemented with 5% horse serum and 2 mM
L-glutamine. DM was changed every 24 hr to keep myotubes healthy.
Under our conditions, myotube formation was complete 48 hr after
switching to DM. The C2C12 myotubes were stimulated with neuregulin
at a final concentration of 2 nM at 37°C. Myotubes used for reporter gene
expression assays were treated for 24 hr after complete fusion.
Transfection procedures. At ;50–70% confluence, C2C12 myoblasts
plated in six well cell culture plates were transiently transfected using the
calcium phosphate method. (Ausubel et al., 1994; Si et al., 1996, 1997).
Myoblasts were cotransfected with an experimental plasmid DNA (3 mg
per well), plus the e-subunit promoter-luciferase transgene (1 mg of DNA
per well) and a control plasmid pCMVb (0.1 mg of DNA per well)
encoding b-galactosidase. The myoblasts were incubated with the cal-
cium phosphate precipitate for 24 hr under normal growth conditions and
then switched to DM to induce myotube formation.
Luciferase and b-galactosidase assays. The luciferase assay was per-
formed using a kit from Promega (Madison, WI) following the manu-
facturer’s instructions. Briefly, 100 ml of cell lysate was mixed in an equal
volume of luciferase substrate solution containing 20 mM tricine, 1.07 mM
(MgCO3)4 Mg (OH)2 z 5 H2O, 2.67 mM MgSO4, 0.1 mM EGTA, 33.3 mM
DTT, 270 mM coenzyme A, 470 mM luciferin, and 530 mM ATP and
placed in a microb luminometer (Wallac, Turku, Finland) to measure
light production for 10 sec. b-galactosidase activity was determined by
hydrolysis of o-nitrophenyl-b-D-galactopyranoside (ONPG) according to
published methods (Sambrook et al., 1989; Si et al., 1996). Briefly, an
aliquot of cell lysate was incubated with 67 mM sodium phosphate, pH
7.5, 1 mM MgCl2, 45 mM b-mercaptoethanol, and 0.88 mg/ml ONPG in
a volume of 300 ml at 37°C until a faint yellow color developed. The
absorbance at 420 nm was measured using a spectrophotometer. Lucif-
erase activity of transgenes was normalized to b-galactosidase activity to
correct for variations in transfection efficiency.
Immunoprecipitations. C2C12 myotubes or wild-type and mutant
mouse fibroblasts were washed two times with cold PBS and then lysed in
cold lysis buffer [50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA,
2 mM sodium orthovanadate, 1% NP-40, 0.25% deoxycholate, 1 mM
pepstatin, 1 mg/ml leupeptin, 2 mg/ml aprotinin, and 1 mM phenylmeth-
ylsulfonyl flouride (PMSF)]. Cell lysates were incubated on ice for 30
min and centrifuged at 13,000 3 g for 10 min at 4°C to remove cell
debris, after which the protein concentration of the supernatant was
determined by the method of Bradford using bovine serum albumin
(BSA) as a standard. For immunoprecipitation, cleared lysates were
incubated with specific antibodies for 1 hr at 4°C and were then incubated
with 50 ml of 50% protein A-agarose beads overnight at 4°C on a rotating
platform. After centrifugation, beads were washed four or five times with
lysis buffer, and bound proteins were eluted with SDS sample.
Western blot analysis. Lysates or immunocomplexes after immunopre-
cipitation were subjected to SDS-PAGE and transferred to nitrocellulose
membranes (Schleicher & Schuell, Keene, NH). Nitrocellulose blots
were incubated for 1 hr in blocking buffer [5% milk in Tris-buffered
saline with 0.1% Tween (TBS-T) or 3% BSA, for anti-phosphotyrosine
antibodies] at room temperature. The blots were then incubated in 1%
milk or BSA with the recommended concentrations of specific primary
antibodies. After washing three times for 15 min with TBS-T, the blots
were incubated with horseradish peroxidase-conjugated donkey anti-
mouse or anti-rabbit IgG (Amersham Pharmacia Biotech, Piscataway,
NJ) followed by washing. Immunoreactive bands were visualized with
enhanced chemiluminescence substrate (Pierce, Rockford, IL).
ERK kinase assay. For kinase assay, ERK kinase was precipitated
with antibody and protein A-agarose beads in HO buffer (50 mM HEPES,
pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% NP-40, 40 mM p-
nitrophenylphosphate, 1 mM pepstatin, 1 mg/ml leupeptin, 0.2 mM sodium
orthovanadate, and 2 mg/ml aqprotinin). The beads were washed twice in
HO buffer and twice with kinase buffer (10 mM HEPES, pH 7.4, and 10
mM magnesium acetate). The assay was performed by mixing the beads
with 1 mg/ml myelin basic protein (MBP), 75 mM ATP, and 2.5 mCi
[g- 32P]ATP in kinase buffer and incubated for 15 min at 30°C. After
centrifugation supernatants were either subjected to SDS-PAGE fol-
lowed by autoradiography or spotted onto P81 Whatman paper followed
by five washes in 180 mM phosphoric acid and one wash in 100% ethanol.
Air-dried P81 paper or excised gel bands were counted in scintillation
cocktail. Both methods gave similar results.
Raf kinase assay. Raf kinase was immunoprecipitated with polyclonal
anti-Raf antibody and protein A-agarose beads in Raf lysis buffer (in mM:
50 Tris–HCl, pH 7.8, 50 b-glycerol phosphate, 1% Triton X-100, 1
sodium orthovanadate, 1 EDTA, 1 DTT, 1 PMSF, 1 mg/ml pepstatin, 1
mg/ml leupeptin, and 2 mg/ml aprotinin). Beads were washed twice in
lysis buffer, two times in lysis buffer with 1 M NaCl, and two times in
kinase the buffer (in mM: 50 Tris–HCl, pH 7.8, 1 MgCl2, and 1 DTT).
Kinase assays were performed by mixing the beads with 4 mg/ml recom-
binant GST-MEK, 100 mM ATP, and 5 mCi [g- 32P] ATP, in the kinase
buffer and incubated for 20 min at 30°C. After the addition of 20 mg/ml
recombinant GST-ERK1, the samples were incubated for an additional
30 min and then subjected to SDS-PAGE.
Ras assay. Active GTP-bound Ras was precipitated by the minimal
Ras-binding domain (RBD) (aa 51–131) of Raf1 (Rooij and Bos, 1997).
Briefly, serum-starved CT and M2 cells were treated with neuregulin (5
nM) or EGF (50 ng/ml) for indicated times and lysed in Ras-binding
buffer (15% glycerol, 50 mM Tris/HCl, pH 7.4, 1% NP-40, 200 mM NaCl,
10 mM MgCl2, 1 mM PMSF, 1 mg/ml pepstatin, 1 mg/ml leupeptin, and 2
mg/ml aprotinin). Cleared lysates were incubated for 1 hr with recombi-
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nant GST-RBD (15 mg/sample) that had been precoupled to glutathio-
ne–agarose beads. After four washes in Ras buffer, bead complexes were
separated on a 12.5% SDS-PAGE and transferred to nitrocellulose
membrane for Western blotting. Ras was detected using the rat mono-
clonal antibody Y13–259 followed by HRP-coupled goat anti-rat anti-
serum (Santa Cruz Biotechnology). Quantification was performed by
image analysis of films by scanning the film with Personal Densitometer
(Molecular Dynamics, Sunnyvale, CA), and the captured image was
analyzed with ImageQuant software (Molecular Dynamics). Each gel
included a series of lanes loaded with increasing amounts of a known
quantity of sample lysate which was later used for calibration during
densitometric analysis.
Protein concentration determination. Protein concentration was mea-
sured by the Bradford method using a Coomassie protein assay reagent
(Pierce) and BSA as a standard (Bradford, 1976).
Immunofluorescence. Mouse diaphragm was isolated and frozen in
isopentane. Cryosections (15 mm) were then thaw-mounted onto posi-
tively charged slides and incubated in blocking solution (2% normal goat
serum in PBS) for 1 hr at room temperature. Sections were incubated for
1 hr with 1:1000 dilution of polyclonal anti-SHP2 in blocking solution at
room temperature. After washing in PBS, sections were incubated with
FITC-conjugated secondary antibody (Zymed Laboratories, San Fran-
cisco, CA) and rhodamine-conjugated a-bungarotoxin in blocking solu-
tion for 1 hr at room temperature. Indirect immunofluorescent images
were captured on 35 mm film using an automatic exposure system.
Exposure times for the FITC images (SHP2) were approximately twice
that used for rhodamine images (a-bungarotoxin).
RESULTS
Stimulation-dependent interaction between SHP2 and
ErbB proteins in C2C12 myotubes
SHP2 is expressed in C2C12 myotubes, a cell culture system
routinely used to study NMJ formation. After stimulation of
myotubes with neuregulin, both ErbB2 and ErbB3, the ErbBs that
are expressed in this cell line, become tyrosine phosphorylated
(Si et al., 1996; S. Won and L. Mei, unpublished observations).
We determined whether SHP2 interacts with the tyrosine-
phosphorylated ErbB proteins. C2C12 myotubes were stimulated
with 2 nM neuregulin for various times, cells lysed, and SHP2-
interacting proteins were coimmunoprecipitated by a monoclonal
anti-SHP2 antibody. The immunocomplex was resolved on SDS-
PAGE, transferred to nitrocellulose, and probed with an anti-
phosphotyrosine antibody. As shown in Figure 1, several proteins
copurified with SHP2, among which were two bands migrating at
;180 kDa. Reprobing of blots with specific antibodies revealed
that they were ErbB2 (;180 kDa) and ErbB3 (;160 kDa) (data
not shown), indicating that SHP2 interacts either directly, or
indirectly with both proteins. Like the tyrosine phosphorylation
of ErbB proteins, this interaction was increased by neuregulin
stimulation (Fig. 1A). Moreover, neuregulin increased the ty-
rosine phosphorylation of SHP2 (Fig. 1A). A protein migrating at
;115 kDa also copurified with SHP2 in a stimulation-dependent
manner (Fig. 1A). This protein appeared to be SHPS-1/SIRP,
which becomes associated with SHP2 after stimulation of cells
with insulin or growth hormone (Baugh et al., 1991; Stofega et al.,
1998).
SHP2 has two SH2 domains. To determine which SH2 domain
interacts with ErbB proteins, we generated recombinant GST
fusion proteins containing the N-terminal (GST-NSH2), the
C-terminal (GST-CSH2), or both (GST-2SH2) SH2 domains.
These proteins were immobilized on agarose beads and incubated
with cell lysates. As shown in Figure 1B, GST-2SH2 was able to
pull down ;180 kDa proteins in a neuregulin stimulation-
dependent manner. The N-terminal SH2 appeared to have a
higher affinity for these proteins than the C-terminal SH2 (Fig.
1B, bottom panel).
Figure 1. SHP2 interaction with ErbB proteins in neuregulin (NRG)-
stimulated muscle cells. A, C2 myotubes were stimulated for the indicated
times with 2 nM neuregulin. Cell lysates were subjected to immunoprecipi-
tation with a SHP2 monoclonal antibody followed by SDS-PAGE and
immunoblot using anti-phosphotyrosine antibody. A doublet was observed
in the 180 kDa range, and subsequent reprobing demonstrated that the
higher molecular weight band comigrated with erbB2, whereas the lower
one comigrated with ErbB3. The 70 kDa protein that showed a stimulation-
dependent increase in phosphotyrosine content was SHP2. Approximately
equal amounts of SHP2 were immunoprecipitated for each time point, as
indicated in the bottom panel. B, Interaction of SHP2 SH2 domains with 180
kDa proteins. C2 myotubes were stimulated with 2 nM neuregulin for 5 min
and then incubated with agarose-bound GST or GST fusion proteins
containing both SHP2 SH2 domains (2SH2), the N-terminal (NSH2), or the
more C-terminal (CSH2) SH2 domain. Bound proteins were eluted in
SDS-sample buffer followed by SDS-PAGE and immunoblot analysis using
an anti-phosphotyrosine antibody. The 180 kDa proteins were determined
to contain ErbB proteins based on parallel experiments with specific
antibodies. No association occurred with GST alone.
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Wild-type SHP2 negatively regulates neuregulin-
stimulated induction of an AChR reporter gene
SHP2 is believed to act as a positive mediator of signaling
responses to various factors, including EGF. Moreover, a positive
role of SHP2 has been shown for factor-induced gene expression
by a/b interferon and prolactin (Ali et al., 1996; David et al.,
1996). We were therefore interested in investigating the possible
role of SHP2 in neuregulin-induced AChR expression in C2C12
myotubes. Cotransfection experiments were performed with var-
ious SHP2 constructs and e416-Luc, an AChR e-subunit 59 flank-
ing region that drives the expression of luciferase (Si et al., 1997).
A b-galactosidase plasmid under the constitutive control of the
cytomegalovirus (CMV) promoter was included in transfections
to control for transfection efficiency and sample handling. Ex-
pression of the luciferase reporter increased to ;2.5-fold after
neuregulin stimulation of vector-transfected cells. As shown in
Figure 2, overexpression of wild-type SHP2 reduced the level of
induction to ;70% of a vector control, although expression of a
SHP2 construct coding for only the catalytic domain was without
effect. Surprisingly, overexpression of a mutant SHP2 that lacks
the N-terminal SH2 domain resulted in a significant increase in
AChR reporter gene expression. These results suggested that
SHP2 may negatively regulate neuregulin signaling. To further
determine the negative role of SHP2 in the regulation of AChR
gene expression, a phosphatase dead SHP2 mutant (SHP2D450–
478) was introduced into C2C12 cells, and the effect on
neuregulin-induced expression of the e416-Luc transgene as-
sessed. Previous studies have shown that a similar SHP2 mutant
functions as a dominant negative mutant in the EGFR signaling
pathway (Bennett et al., 1996). Expression of SHP2D450–478
also resulted in a higher fold of induction (Fig. 2), as did a
catalytically impaired SHP2 construct (SHP2Asp426Ala) con-
taining an alanine substituted for a catalytically essential aspartic
acid residue (data not shown) (Barford et al., 1994; Garton et al.,
1996). Because the wild-type SHP2 was inhibitory, these results
suggest that the N-terminal SH2 domain of SHP2 is required for
the negative regulatory effect of SHP2 on neuregulin signaling.
Enhanced ERK activation in response to neuregulin in
fibroblasts expressing a mutant SHP2
SHP2 mutant mice die early in embryonic development [embry-
onic day 9.5 (E9.5)] when it is almost impossible to isolate
primary muscle cells for culture. To confirm the negative regula-
tory role of SHP2 in the neuregulin signaling pathway, we studied
neuregulin and EGF signaling in mouse fibroblast cells that
express a mutant SHP2 lacking the N-terminal SH2 domain
(amino acids 46–110) (Saxton et al., 1997). This cell line is
thought to represent a partial or nearly total loss of SHP2 func-
tion. Previous studies of these cells have shown a positive role of
the SHP2 N-terminal SH2 domain in EGF signaling (Shi et al.,
1998). Use of the mutant cells to study SHP2 function in neu-
regulin signaling precluded the necessity of overexpressing dom-
inant negative mutants of SHP2 that might lead to nonspecific
effects and, in addition, facilitated biochemical studies. The SHP2
mutant cells (M2) express a 57 kDa SHP2 protein at a reduced
level compared to the full-length phosphatase expressed by the
wild-type cells (CT) (Fig. 3A) (Shi et al., 1998). The two cell lines
express comparable amounts of ErbB2 and ErbB3 (Fig. 3A). No
ErbB4 was detected in either cell line. Both lines have previously
been shown to express similar levels of EGFR, ERK1, and ERK2
(Shi et al., 1998).
To study the role of SHP2 in neuregulin-mediated activation of
the MAP kinase pathway, CT and M2 cells were treated with
neuregulin and assayed for ERK activity using an in vitro kinase
assay of immunoprecipitated ERK. The basal ERK kinase activ-
ity was at a low and similar level in either cell line. Parallel
experiments demonstrated that EGF elicited ERK activation in
both CT and M2 cells, however the activation seen in M2 cells
was significantly attenuated, in agreement with previous results
(Fig. 3B) (Shi et al., 1998). CT cells demonstrated only a modest
activation of ERK in response to neuregulin, probably because of
the relatively low expression level of ErbB3 (1.7 6 0.2-fold above
the basal; Fig. 3B). Strikingly, the mutant M2 cells displayed a
fairly robust response (8.0 6 2.3-fold) to neuregulin, despite the
fact that they express ErbB2 and ErbB3 at similar levels as
Figure 2. Negative regulation of the NRG-induced expression of an AChR e subunit reporter gene by SHP2. C2 cells were cotransfected with various
SHP2 constructs and e416-luc, which contains the e-subunit 59 flanking region driving the expression of luciferase. A b-galactosidase plasmid under the
constitutive control of the CMV promoter was included to control for transfection efficiency and sample handling. Subsequent to myotube formation,
transfectants were treated with or without 2 nM neuregulin for 24 hr. Luciferase activity was normalized to b-galactosidase activity. These data represent
the mean 6 SD of at least three independent experiments. Wild-type SHP2 reduced the neuregulin-induced expression to 72 6 7% of vector control,
whereas a catalytically inactive mutant (SHP2D450–478) and a mutant lacking the N-terminal SH2 domain (SHP2DNSH2) enhanced the reporter
expression to 155 1 29% and 190 1 35%, respectively. Coexpression of the SHP2 catalytic domain (SHP2PTP) had a negligible effect. *p , 0.05.
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wild-type cells. Also worth noting is the difference in the time
courses of neuregulin-stimulated ERK activation in CT and M2
cells, with the CT cells showing a relatively delayed response.
Because the polyclonal ERK antibody used for immunoprecipi-
tation in these assays preferentially precipitates ERK1 (p44 MAP
kinase), we confirmed our results using an activation-specific
antibody that recognizes both ERK1 and ERK2. Western blots of
cell lysates from CT and M2 cells treated as for the in vitro kinase
assays were probed with the E10 monoclonal antibody. This
antibody is highly specific for ERK1 and ERK2 that are doubly
phosphorylated on threonine and tyrosine residues correspond-
ing to Thr202/Tyr204 of human p44 and p42 MAP kinases
(Payne et al., 1991). Phosphorylation at these sites is essential for
maximum activation of ERK1 and ERK2. As shown in Figure 3C,
results from these experiments were consistent with the ERK
activity data, providing further evidence of a negative role of
SHP2 in neuregulin-stimulated ERK activation.
Enhanced activation by neuregulin of Raf and Ras in
M2 mutant cells
In light of the opposing responses of M2 and CT cells to EGF and
neuregulin, we were interested in characterizing points of diver-
gence upstream of ERK activation. To this end, we characterized
activation of Raf, an ERK kinase kinase, in response to neuregu-
lin and EGF. Raf is a serine–threonine kinase that phosphory-
lates and activates the dual specificity kinase MEK (MAPKK)
(Luo et al., 1996) which, in turn, phosphorylates and activates
ERK. Raf was purified by immunoprecipitation with a polyclonal
anti-Raf antibody, and its activity was assayed by a standard
method with [ 32P]-labeled ERK1 as a readout (Luo et al., 1996).
Raf activity in CT cells was increased within 5 min after treat-
ment with EGF (Fig. 4). The Raf activation by EGF was less in
M2 cells. Neuregulin activation of Raf was barely detectable in
CT cells but was prominent in M2 cells. These experiments
demonstrated that Raf activation followed a similar pattern to
that of ERK activation in response to EGF and neuregulin,
suggesting that the site of SHP2 differential regulation is up-
stream of Raf kinase.
Ras acts proximally downstream to receptor activation through
its conversion to the active, GTP-bound, state by the receptor-
associated Grb2-SOS complex (Buday and Downward, 1993;
Egan et al., 1993). Importantly, previous studies have indicated
that the positive effects of wild-type SHP2 act upstream of, or
parallel to, Ras (Noguchi et al., 1994; Yamauchi et al., 1995).
Thus, Ras may represent an important convergence point for
receptor-generated signals acting through SHP2. We used a
method developed by Rooij and Bos (1997) that exploits the high
affinity of the Raf1 RBD (aa 51–131) for GTP-bound Ras (Herr-
mann et al., 1995). The Raf RBD binds to GDP-bound Ras,
Figure 3. ERK activation in response to NRG and EGF in CT and M2
fibroblasts. A, Immunoblot analysis demonstrating the relative expression
of ErbB2, ErbB3, and SHP2 in SHP2 mutant M2 cells, and wild-type CT
cells. ErbB4 expression was not detected in either cell line. Notice the
lower apparent molecular weight of the mutant SHP2, resulting from
deletion of amino acids 46–110 of the N-terminal SH2 domain. B, ERK
activation assayed using MBP as a substrate. Serum-starved CT (open
circles) and M2 (closed circles) fibroblasts were stimulated with EGF or
neuregulin for the indicated times. ERK1 was immunoprecipitated from
cell lysates and subjected to an in vitro kinase assay using MBP as a
substrate. Shown are the averages of ERK1 activity from four to six
independent experiments. C, ERK activation assayed by anti-phospho-
ERK antibodies. Lysates from cells treated as in B were subjected to
SDS-PAGE and Western blot analysis with an antibody that specifically
recognizes activated ERK1 and ERK2. The same membrane was stripped
and reprobed with a different antibody that recognizes both phosphory-
lated and nonphosphorylated ERK1 and ERK2. Shown is a Western blot
from a representative experiment that was repeated three times with
similar results.
Figure 4. EGF- and NRG-stimulated Raf kinase activity in CT and M2
fibroblasts. Serum-starved CT and M2 cells were treated with EGF or
neuregulin for 5 and 10 min, lysed, and subjected to immunoprecipitation
with an anti-Raf antibody. GST-ERK1 was added to assay Raf kinase
activity 20 min after the addition of [g-32P]ATP and GST-MEK. Shown
is the autoradiograph of samples resolved on SDS-PAGE from a repre-
sentative experiment that was repeated three times with similar results.
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however, with three orders of magnitude lower affinity. GST-Raf-
RBD was used to purify active Ras from control and treated CT
and M2 cells that was then analyzed by Western blot using Ras
antibodies. Neuregulin stimulation of CT cells produced a barely
detectable increase in active Ras, whereas the increase after EGF
treatment was quite strong. In contrast, an increase in active Ras
was readily apparent after both neuregulin and EGF treatment of
M2 cells (Fig. 5). In addition, the time dependence of Ras
activation was qualitatively similar to that seen of ERK activity.
With each experiment, lysate equivalents were run in parallel to
provide a standard for calibration. Using scanning densitometry,
a semiquantitative analysis was performed, and the results are
illustrated in bar graph form in Figure 5B. The inverse relation of
EGF and neuregulin-stimulated Ras activation is readily appar-
ent. Thus, the overall pattern of Ras activation was consistent
with downstream components of the ERK pathway, indicating
that the primary divergence point was upstream of Ras.
Hyperphosphorylation of ErbB proteins in M2
mutant cells
After ligand presentation the ErbB family of receptors become
tyrosine-phosphorylated, thereby forming docking sites for SH2
domain-containing proteins such as the adaptor proteins Shc and
Grb2 (Buday and Downward, 1993; Won and Mei, unpublished
observations). Tyrosine phosphorylation is therefore considered
a measure of receptor activation. To study the regulation of
receptor activation by SHP2, we immunoprecipitated EGFR,
ErbB2, and ErbB3 from CT and M2 cells stimulated with the
appropriate growth factor and determined their tyrosine phos-
phorylation. EGFR demonstrated a dramatic increase in tyrosine
phosphorylation in as little as 1 min, whereas there was a modest
increase in tyrosine phosphorylation of ErbB2 and ErbB3 in
wild-type cells (Fig. 6, lef t lanes). This increase in ErbB protein
tyrosine-phosphorylation paralleled the activation of ERKs.
Ligand-stimulated tyrosine phosphorylation of ErbB2 and ErbB3
was significantly higher in mutant cells than in wild-type cells,
whereas phosphorylation of EGFR appeared to be modestly
increased at later time points (Fig. 6, right lanes). Additionally,
phosphorylation of ErbB3 occurred relatively later in wild-type
cells. Probing of the membranes with a SHP2 monoclonal anti-
body revealed that SHP2 coprecipitated with ErbB2 and ErbB3 in
both mutant and wild-type cells, suggesting the C-terminal SH2
domain is able to interact with those proteins. The lower amount
of mutant SHP2 coprecipitating with ErbB2 and ErbB3 is likely a
combination of its lower level of expression and a reduced affinity
for the activated receptors. SHP2 coprecipitated with EGFR in
wild-type cells; in contrast, no such interaction was seen in cells
expressing the mutant SHP2. These results suggest that ErbB
proteins are substrates of SHP2 and in addition, that the mutant
SHP2 protein is incapable of interacting with the EGFR or forms
a weaker association that does not survive immunoprecipitation.
SHP2 is localized at the neuromuscular junction
Neuregulin receptor ErbB proteins, as well as other tyrosine-
phosphorylated proteins, are localized to the neuromuscular junc-
tion (Qu et al., 1990; Altiok et al., 1995; Moscoso et al., 1995; Zhu
et al., 1995). We hypothesized that SHP2, containing two SH2
domains, binds to synaptic tyrosine-phosphorylated proteins and
thus becomes concentrated at the NMJ. We therefore studied
SHP2 localization using immunofluorescence techniques. Muscle
sections were incubated with affinity-purified anti-SHP2 antibody
and rhodamine-conjugated a-bungarotoxin, which labels the
AChR. The SHP2 immunoreactivity was visualized with an
FITC-conjugated secondary antibody. As shown in Figure 7,
SHP2 showed a strikingly similar pattern of labeling (Fig. 7A) to
AChRs labeled with a-bungarotoxin (Fig. 7A9). Merging of the
two images indicated that SHP2 is localized in precise register
with the AChR at the neuromuscular junction (data not shown).
Specificity of the staining of SHP2 at the NMJ was demonstrated
by the fact that the preimmune serum did not produce any
staining above the background (Fig. 7B,B9). Furthermore, the
SHP2 staining was diminished by preabsorbing the antibody with
the immunogen (Fig. 7C,C9).
DISCUSSION
In this paper we report several lines of evidence implicating the
involvement of SHP2 in neuregulin signaling at the NMJ. We
Figure 5. Neuregulin- and EGF-stimulated Ras activity in CT and M2
fibroblasts. A, CT and M2 cell lysates were incubated with Raf-RBD
immobilized on agarose beads. Bound protein was eluted in SDS-sample
buffer followed by SDS-PAGE and Western blot analysis with a rat
monoclonal anti-Ras antibody. B, Comparison of Ras activation in CT
and M2 cells in response to neuregulin and EGF (5 min). Each Western
blot included varying amounts of lysate to calibrate each experiment for
subsequent scanning densitometric analysis. Shown is the average of three
independent experiments. *p , 0.05.
Tanowitz et al. • SHP2 and Neuregulin Signaling J. Neurosci., November 1, 1999, 19(21):9426–9435 9431
demonstrate that association of SHP2 with both ErbB2 and
ErbB3 is increased after neuregulin stimulation and that expres-
sion of mutant SHP2 proteins with defective phosphatase activity
or deletion of the N-terminal SH2 domain result in increases in
neuregulin-stimulated transcriptional activation in C2C12 myo-
tubes. The negative regulatory role of SHP2 in the neuregulin
signaling pathway was confirmed in fibroblasts expressing wild-
type and mutant SHP2. Furthermore, our data suggests that the
point of SHP2-negative regulation occurs at the receptor level, in
contrast to signal-enhancing effects of SHP2 in the EGF signaling
pathway, which appears to occur at the level of Ras activation.
Finally, SHP2 was found to be localized to the neuromuscular
junction, where neuregulin receptors are known to be concen-
trated and synapse-specific signal-transduction presumably
occurs.
SHP2 at the neuromuscular junction
Tyrosine phosphorylation plays a paramount role in formation and
stability of the neuromuscular synapse. This is first suggested by
the immunohistochemical finding that tyrosine-phosphorylated
proteins are concentrated at the NMJ. Both innervation of mus-
cle during development and of myotubes cocultured with gangli-
onic neurons increases the phosphotyrosine immunostaining at
synaptic sites (Qu et al., 1990). Several synapse-specific tyrosine
kinases have been identified. The expression of ErbB2, ErbB3,
and ErbB4 receptor tyrosine kinases is restricted to the adult
NMJ (Altiok et al., 1995; Moscoso et al., 1995; Zhu et al., 1995),
as is MuSK, a transmembrane tyrosine kinase whose activity is
stimulated by agrin and that is both necessary and sufficient to
cause clustering of the AChR (DeChiara et al., 1996; Jones et al.,
1999). In addition, two cytoplasmic tyrosine kinases, Fyk and
Fyn, bind via their SH2 domains to the AChR which itself is a
substrate of tyrosine phosphorylation (Swope and Huganir,
1994). In contrast to the extensive study of tyrosine kinases that
may be involved in NMJ formation, little is known of the relevant
protein tyrosine phosphatases. We previously purified a protein
tyrosine phosphatase from Torpedo electric organ that specifi-
cally dephosphorylates the AChR (Mei and Huganir, 1991).
Moreover, the protein tryrosine phosphatase (PTP) activity in
skeletal muscle appears to be regulated by motoneurons, because
surgical denervation causes an increase in PTP activity in rat
hindlimb muscles (Tanowitz and Mei, 1996). In C2C12 cells, we
have previously demonstrated that inhibition of PTP activity by
vanadate enhanced the basal and neuregulin-induced expression
of an AChR reporter gene (Si et al., 1996). Here we have
Figure 6. Neuregulin (NRG)- and
EGF-stimulated receptor tyrosine phos-
phorylation and association with SHP2.
CT and M2 cells were stimulated with
neuregulin or EGF for the indicated
times. Cell lysates were subjected to im-
munoprecipitation with anti-ErbB2,
anti-ErbB3, or anti-EGFR polyclonal
antibodies. Immunocomplexes were re-
solved by SDS-PAGE, transferred to ni-
trocellulose, and probed with anti-
phosphotyrosine and anti-SHP2
antibodies. Half of each immunocom-
plex was run on a parallel gel and
probed with same antibody used for im-
munoprecipitation to demonstrate equal
amount of immunoprecipitated protein.
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demonstrated that SHP2 negatively regulates neuregulin signal-
ing, providing a possible explanation for this effect of vanadate
treatment. This would also be consistent with the finding that
overexpression of protein tyrosine phosphatases reduces expres-
sion of adult-type nicotinic receptors in primary muscle cultures
(Sapru et al., 1994). Neuregulin is secreted by the somatic mo-
toneuron and deposited in the synaptic basal lamina where it
persists long after loss of the presynaptic neuron (Jo et al., 1995).
Regulation of the neuregulin signal by changes in presynaptic
deposition would appear to be an inefficient mechanism. The
presence of SHP2 at the NMJ may reflect a role in fine tuning or
adjusting the “gain” of the inductive effect of neuregulin.
If the concentration of SHP2 at the NMJ is a result of its
association with ErbB receptors, synaptic ErbB proteins should
exist in a more or less constitutively phosphorylated state. Al-
though there is no direct evidence that ErbB proteins are consti-
tutively phosphorylated at the NMJ, several lines of evidence
support this hypothesis. Neuregulin is concentrated in the syn-
aptic basal lamina (Goodearl et al., 1995; Jo et al., 1995), and
ErbB proteins are concentrated at the NMJ (Moscoso et al., 1995;
Zhu et al., 1995). Thus, it is a logical inference that synaptic
ErbBs are constitutively phosphorylated and it is likely, therefore,
that SHP2 localizes to the NMJ by an interaction with activated
ErbB proteins. The concentration of SHP2 at the NMJ could
indicate additional functions of SHP2, such as regulating the
formation of cytoskeletal specializations that serve to anchor the
AChR to the synapse. Huganir and his colleagues (Qu et al.,
1990) have shown that tyrosine-phosphorylated proteins are con-
centrated at the NMJ. In addition to ErbB proteins, tyrosine-
phosphorylated proteins at the NMJ include the AChR (Wallace
et al., 1991) and MuSK (DeChiara et al., 1996). SHP2 may
interact with and regulate the function of these proteins. Peng
and his colleagues (Dai and Peng, 1998) recently proposed that a
diffusible signal, which may be a cytoplasmic protein tyrosine
phosphatase, is involved in the dispersal of spontaneous AChR
clusters (“hot spots”). By virtue of its synaptic concentration,
SHP2 may be an attractive candidate for this phosphatase. Within
such a scenario, synaptically localized phosphoproteins concen-
trate SHP2, which in turn disrupts nearby spontaneous clustering
and helps to sculpt the synaptic distribution of AChRs and/or
other synaptic proteins.
Mechanisms of SHP2 regulation of
neuregulin signaling
Importantly, we found that the mutant SHP2 protein lacking the
N-terminal SH2 domain was capable of interacting with ErbB2
and ErbB3 and thus could, in theory, interfere with wild-type
SHP2 function or substitute for it. If deletion of the N-terminal
SH2 domain results in a SHP2 protein that can substitute for
wild-type, overexpression of either protein would be expected to
produce similar results. This was clearly not the case because
overexpression of wild-type SHP2 exerted a negative effect on the
AChR e reporter in myotubes, yet overexpression of the
N-terminal SH2 domain deletion mutant yielded a nearly 100%
increase in neuregulin-stimulated transgene expression. Neither
is it likely that the effect of mutant SHP2 is caused by a loss of
proper SH2-mediated localization because expression of the PTP
region alone had negligible effect. A reasonable interpretation is
that the SHP2DSH2, retaining the C-terminal SH2 domain, was
able to displace the endogenous protein and interfere with its
negative regulatory effect. The increased receptor tyrosine phos-
phorylation in M2 cells indicates that the negative influence of
wild-type SHP2 is mediated by dephosphorylation and inactiva-
tion of ErbB2 and/or ErbB3. The mutant protein is perhaps
Figure 7. SHP2 localization at the NMJ. Mouse dia-
phragm sections were incubated with affinity-purified anti-
SHP2 antibody ( A) and rhodamine-conjugated
a-bungarotoxin (a-BTX) (A9), which labels the AChR. The
SHP2 immunoreactivity was visualized by FITC-
conjugated secondary antibody. B shows staining by preim-
mune serum, and C shows anti-SHP2 antibodies pread-
sorbed with the immunogen. The exposure time for SHP2
immunoreactivity was approximately twice that of
a-bungarotoxin labeling of the AChR, as determined by an
automatic exposure system.
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incapable of dephosphorylating the ErbB receptors because of
improper alignment or targeting of the catalytic region with the
relevant phosphotyrosine(s). Ideally, the mechanism of SHP2
regulation of AChR subunit gene expression should be examined
in muscle cells isolated from SHP2 mutant mice. Unfortunately,
early embryonic lethality prevents the isolation of primary muscle
cells for culture. The fibroblasts used in the present study were a
viable alternative because they express both ErbB2 and ErbB3
and exhibit neuregulin responses.
It is possible that SHP2 exerts both positive and negative
influences after neuregulin signaling where the dominant, nega-
tive role requires the N-terminal SH2 domain, whereas the
C-terminal SH2 domain is capable of mediating a positive effect.
ErbB2 has a number of tyrosine residues that when phosphory-
lated may become either positive or negative regulatory sites for
downstream signaling. Deletion of a negative site leads to in-
creased Grb2 and Shc binding to the activated receptor (Dankort
et al., 1997). Alternatively, the target of SHP2 catalytic activity
could be one or more phosphotyrosines that regulate ErbB ty-
rosine kinase activity. The phosphorylation of residues in the
activation motif, or so called “A-loop”, of the catalytic domain is
central to the activation of many protein kinases (Johnson et al.,
1996), including the insulin receptor (Hubbard et al., 1994).
Although the catalytic activity of SHP2 is clearly important for
both positive and negative influences, a role for SHP2 tyrosine
phosphorylation cannot be discounted. The N-terminal deletion
mutant displayed increased tyrosine phosphorylation after
growth factor treatment (data not shown). This was also reported
of the same mutant following PDGF treatment of primary fibro-
blasts (Saxton et al., 1997). SHP2 may function as an adapter and
has been shown to bind Grb2. Such an adaptor function of SHP2
has been proposed for PDGF signaling (Bennett et al., 1994),
although a functional requirement of SHP2 tyrosine phosphory-
lation has never been demonstrated. Tyrosine phosphorylation of
CORKSCREW (CSW), the Drosophila SHP2 homolog, occurs
after stimulation of the TORSO receptor tyrosine kinase. Phos-
phorylated CSW may participate in linking DRK, the Drosophila
Grb2 homolog, to TORSO (Cleghon et al., 1998). Whether SHP2
can function as an adapter in the neuregulin signaling pathway
remains to be determined.
In summary, the protein tyrosine phosphatase SHP2 is concen-
trated at the NMJ, negatively regulates neuregulin-induced
AChR expression, and may serve other functions at the synapse.
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